Rene Russo bought $25k of XLO
PRESIDENT AND CEO at Xilio Therapeutics, Inc.. 36,289 shares at an average of $0.68, traded Jun 16, 2025, filed Jun 18, 2025.
Score components
- +25RoleCEO
- 0Trade size$25k at market
- +3Relative to holdingsHoldings up 15%
- +18Price context6% above the 52-week low; 54% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-017704, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 16, 2025 | POpen-market purchase Common Stock | +36,289 | $0.68 | $25k | 281,172 | Jun 18, 2025 |
Related signals
Other insiders at Xilio Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | Xilio Therapeutics, Inc. | James Samuel Shannon director | $48k 70,000 shares | - | |
| 0Weak | Xilio Therapeutics, Inc. | Kevin M. Brennan SVP, FINANCE AND ACCOUNTING | $1,774 1,803 shares | -36% | |
| 5Weak | Xilio Therapeutics, Inc. | Christopher James Frankenfield Chief Financial Officer | $6,841 6,954 shares | -36% | |
| 38Weak | XLObuy Xilio Therapeutics, Inc. | Gilead Sciences, Inc. owner | $1.8M 1,759,978 shares | +24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.